NCT01615978 - Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

liraglutide

5 mcg/kg daily for 14 days. Injected subcutaneously once daily

DRUG

liraglutide

Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily

DRUG

placebo

Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1

Trial Locations (1)

Novo Nordisk Investigational Site, Tokyo